NDC product
KALI PHOS
NDC 15631-2804 · Rxhomeo Private Limited d.b.a. Rxhomeo, Inc
Key facts
| Product NDC | 15631-2804 |
|---|---|
| Proprietary name | KALI PHOS |
| Nonproprietary name | KALI PHOS |
| Substances | POTASSIUM PHOSPHATE, DIBASIC |
| Dosage form | LIQUID |
| Route | ORAL |
| Labeler | Rxhomeo Private Limited d.b.a. Rxhomeo, Inc |
| Product type | HUMAN OTC DRUG |
| Marketing category | UNAPPROVED HOMEOPATHIC |
| Pharmacologic classes | Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Osmotic Activity [MoA], Osmotic Laxative [EPC], Potassium Compounds [CS], Potassium Salt [EPC] |
| Marketing start | May 23, 2024 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: